INmune Bio Shares Drop 28% After FDA Puts XPro1595 Application on Hold
May 24 2022 - 08:20AM
Dow Jones News
By Chris Wack
INmune Bio Inc. shares were down 28% to $5.20 in premarket
trading Tuesday after the company said the U.S. Food and Drug
Administration requested additional information for chemistry
manufacturing and controls of the newly manufactured XPro1595.
The company said that as part of the communication, the agency
placed its investigational new drug application to initiate its
Phase 2 clinical trial of XPro in patients with Alzheimer's Disease
in the U.S. on clinical hold.
The FDA indicated it will provide an official clinical hold
letter to INmune in about 30 days, the company said.
INmune said it plans to provide additional updates pending
discussion with the FDA, and its Phase 2 trial of XPro remains open
in Australia and continues to enroll patients.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 24, 2022 08:05 ET (12:05 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.